Author

R. D. Cardin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

A. S. Anderson· 2 shared D. K. Rai· 2 shared K. M. White· 2 shared A. Garcia-Sastre· 1 shared A. Gribenko· 1 shared B. A. Stanfield· 1 shared B. Kreiswirth· 1 shared B. L. McGovern· 1 shared

Activity by Year

2022-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

A. S. Anderson

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

MicrobiologybioRxivPreprintMar 3, 2022

Development of a mouse salivary gland-derived mesenchymal cell line for immunological studies of murine cytomegalovirus

T. M. White, B. A. Stanfield, C. M. Bonavita…·R. D. Cardin

This paper develops a BALB/c-derived mouse salivary gland mesenchymal cell line for improved MCMV immunological studies.

DOI 10.1101/2022.03.03.482882

mouseexperimental assay

𝕏 PostBluesky

MicrobiologybioRxivPreprintJan 17, 2022

Nirmatrelvir, Molnupiravir, and Remdesivir maintain potent in vitro activity against the SARS-CoV-2 Omicron variant

R. Rosales, B. L. McGovern, M. L. Rodriquez…·K. M. White

This study evaluates the antiviral activity of nirmatrelvir, molnupiravir, and remdesivir against the SARS-CoV-2 Omicron variant and confirms their potency.

DOI 10.1101/2022.01.17.476685

experimental assaydrug response / drug discovery

𝕏 PostBluesky

MicrobiologybioRxivJan 17, 2022

Nirmatrelvir, an orally active Mpro inhibitor, is a potent inhibitor of SARS-CoV-2 Variants of Concern

D. K. Rai, I. Yurgelonis, P. McMonagle…·R. D. Cardin

This paper evaluates the antiviral activity of Nirmatrelvir against multiple SARS-CoV-2 variants using qRT-PCR in VeroE6 cells, showing potent inhibition across all tested variants.

DOI 10.1016/j.antiviral.2026.106517

experimental assaydrug response / drug discovery

𝕏 PostBluesky